ArriVent BioPharma's Strategic Licensing and Partnerships Position It for Growth in ADC Development

TipRanksJan 22 08:35 ET

ArriVent BioPharma Analyst Ratings

BenzingaJan 22 07:46 ET · Ratings

H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $39

Moomoo NewsJan 22 07:31 ET · Ratings

ArriVent BioPharma's Strategic Expansion and Promising Clinical Results Justify Buy Rating and Increased Price Target

TipRanksJan 22 07:15 ET · Ratings

Express News | Arrivent Biopharma, Inc. : H.c. Wainwright Raises Target Price to $39 From $36

ReutersJan 22 06:58 ET

ArriVent BioPharma Enters Licensing Deal With Lepu Biopharma for Gastrointestinal Cancer Drug

MT NewswiresJan 22 03:46 ET